Viaderma Inc
ViaDerma, Inc., through its subsidiary, manufactures and sells pharmaceutical related products in the United States. The company's lead product is Vitastem, a tetracycline and topical delivery technology for antibiotics to pain relief, skincare, and other. It is also developing various products for vitiligo, psoriasis, eczema, and other skin conditions using SkinPass topical delivery system, as w… Read more
Market Cap & Net Worth: Viaderma Inc (VDRM)
Viaderma Inc (PINK:VDRM) has a market capitalization of $22.21 Million ($22.21 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #49758 globally and #15197 in its home market, demonstrating a -18.18% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Viaderma Inc's stock price $0.02 by its total outstanding shares 1233713103 (1.23 Billion).
Viaderma Inc Market Cap History: 2015 to 2025
Viaderma Inc's market capitalization history from 2015 to 2025. Data shows growth from $3.45 Million to $22.21 Million (23.19% CAGR).
Viaderma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Viaderma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
22.60x
Viaderma Inc's market cap is 22.60 times its annual revenue
1.02x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
3312.39x
Viaderma Inc's market cap is 3312.39 times its annual earnings
10.35x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.45 Million | $191.78K | $27.12K | 18.01x | 127.37x |
| 2016 | $3.08 Million | $251.98K | -$121.81K | 12.24x | N/A |
| 2017 | $16.66 Million | $44.69K | -$1.52 Million | 372.67x | N/A |
| 2018 | $3.58 Million | $45.97K | -$3.00 Million | 77.82x | N/A |
| 2019 | $1.85 Million | $10.39K | -$599.27K | 178.02x | N/A |
| 2020 | $2.47 Million | $11.47K | -$431.67K | 215.16x | N/A |
| 2021 | $11.10 Million | $514.01K | -$994.18K | 21.60x | N/A |
| 2022 | $7.40 Million | $540.65K | $590.67K | 13.69x | 12.53x |
| 2023 | $13.57 Million | $600.50K | $4.10K | 22.60x | 3312.39x |
Competitor Companies of VDRM by Market Capitalization
Companies near Viaderma Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Viaderma Inc by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Viaderma Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Viaderma Inc's market cap moved from $3.45 Million to $ 22.21 Million, with a yearly change of 23.19%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $22.21 Million | +91.49% |
| 2024 | $11.60 Million | -14.55% |
| 2023 | $13.57 Million | +83.33% |
| 2022 | $7.40 Million | -33.33% |
| 2021 | $11.10 Million | +350.00% |
| 2020 | $2.47 Million | +33.33% |
| 2019 | $1.85 Million | -48.28% |
| 2018 | $3.58 Million | -78.52% |
| 2017 | $16.66 Million | +440.00% |
| 2016 | $3.08 Million | -10.71% |
| 2015 | $3.45 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Viaderma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $22.21 Million USD |
| MoneyControl | $22.21 Million USD |
| MarketWatch | $22.21 Million USD |
| marketcap.company | $22.21 Million USD |
| Reuters | $22.21 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.